David Soergel, MD

Bio:

Dr. Soergel serves as Executive Vice President and Chief Medical Officer at Madrigal Pharmaceuticals, where he leads the company’s medical, clinical development and regulatory strategy. He joined Madrigal from Novartis, where he was Executive Vice President and Global Head of Cardiovascular, Renal and Metabolism Development, overseeing 10 late-stage programs. At Novartis, he led evidence generation strategies supporting the expansion of Entresto and advanced multiple novel therapies for cardiovascular and renal diseases through approval. He also led development activities for the acquisitions of The Medicines Company and Chinook Therapeutics.
Previously, Dr. Soergel held leadership roles in biotechnology, including Senior Vice President of Clinical Development and Chief Medical Officer at Trevena, where he oversaw development of novel treatments for pain and other conditions. He began his career in early-stage clinical development and translational medicine at GlaxoSmithKline. Dr. Soergel trained in pediatrics, pediatric cardiology and heart failure and transplant medicine at Johns Hopkins Hospital and the Children’s Hospital of Philadelphia.